Twice-yearly injection of Gilead’s lenacapavir achieves 100% protection in landmark HIV prevention trial
Gilead Sciences’ twice-yearly injectable lenacapavir demonstrated complete protection against HIV infection in a landmark Phase 3 trial, potentially revolutionising HIV prevention strategies for vulnerable populations.
